Mr. Sachs joined our board in 1998 and is the board's lead independent director. Mr. Sachs is a General Partner at Charles River Ventures, a venture capital firm he joined in 1999. From 1998 to 1999, he served as Executive Vice President and General Manager of Ascend Communications, Inc. From 1997 until 1998, Mr. Sachs served as President and Chief Executive Officer of Stratus Computer, Inc. From 1995 to 1997, he served as Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. From 1993 to 1995, he served as President and Chief Executive Officer of Xylogics, Inc. Mr. Sachs holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University and an M.B.A. from Northeastern University.

Dr. Garber joined our board in 2017. He is currently the Provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, Professor of Public Policy in the Harvard Kennedy School of Government, and a Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health. From 1998 until he joined Harvard in 2011, he was the Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University. Dr. Garber is a member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians and the American Academy for Arts and Sciences. He is a Fellow of the American Association for the Advancement of Science, the American College of Physicians and the Royal College of Physicians. Dr. Garber is also a Research Associate with the National Bureau of Economic Research and served as founding Director of its Health Care Program for 19 years. He also has served as a member of the National Advisory Council on Aging at the National Institutes of Health, as a member of the Board of Health Advisers of the Congressional Budget Office and as Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services. Dr. Garber has been a member of the board of directors of Exelixis, Inc., a biopharmaceutical company, since 2005. Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D., all in economics, from Harvard University, and an M.D. with research honors from Stanford University.

Mr. Carney joined our board in 2019. Mr. Carney was the Chief Acquisition Officer of Carney Technology Acquisition Corp. II, a special purpose acquisition corporation, from October 2020 until February 2023. Mr. Carney was the Chief Executive Officer of ChaSerg Technology Acquisition Corp., a technology acquisition company, from September 2018 until March 2020. He was the Chief Executive Officer of Brocade Communications Systems Inc., a global supplier of networking hardware and software, from January 2013 until November 2017, when it was acquired by Broadcom. Prior to Brocade, Mr. Carney served as Chief Executive Officer of Xsigo Systems, a cloud-based infrastructure solutions provider, until its acquisition by Oracle in 2012. He has also served as the Chief Executive Officer and Chairman of Micromuse Inc., a software solutions provider for business and service assurance, until its acquisition by IBM. Earlier in his career he had held senior leadership roles at Juniper Networks, Inc., Nortel Networks Inc. and Bay Networks, Inc. Mr. Carney serves as a member on the board of directors of Visa Inc. and Grid Dynamics Holdings, Inc. Mr. Carney was a member of the Board of Directors of Nuance Communications Inc., a publicly traded AI-enabled communication company, until it was acquired by Microsoft Corp in March 2022. He holds a Bachelor of Science degree in electrical engineering technology from Wentworth Institute of Technology, a Master of Science degree in applied business management from Lesley College, and an Honorary Doctorate degree in engineering from Wentworth Institute of Technology.

Dr. Bhatia joined our board in 2015. She currently serves as the John J. and Dorothy Wilson Professor of Engineering at the Massachusetts Institute of Technology (MIT), Director of the Marble Center for Cancer Nanomedicine, and an investigator for the Howard Hughes Medical Institute. She also holds appointments at the Koch Institute for Integrative Cancer Research, the Broad Institute, the Wyss Institute and Brigham and Women’s Hospital. In 2018, Dr. Bhatia was on sabbatical from MIT while she served as a co-founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring. Prior to joining MIT in 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005. Dr. Bhatia holds an Sc.B. in biomedical engineering from Brown University, an S.M. in mechanical engineering and a Ph.D. in biomedical engineering from MIT, and an M.D. from Harvard Medical School. Dr. Bhatia was the 25th person in history to be an elected member of all three U.S. National Academies: the National Academy of Science, the National Academy of Medicine and the National Academy of Engineering. She has been honored with the Lemelson-MIT Prize, the Heinz Medal and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields.

Charlie has deep corporate finance and health care experience, including more than a decade in public and private company Chief Financial Officer roles. He joined Vertex in 2019 and oversees the accounting, finance, internal audit, investor relations, business development transactions and alliance management, and global security and facilities functions. 

He holds a B.S. in accounting from Boston College and an M.B.A. from Harvard Business School. Before joining the Vertex leadership team, he held leadership roles at Ortho Clinical Diagnostics (a Carlyle Group portfolio company), Bruker Corporation, Progress Software Corporation and Millipore Corporation. 

In addition to his responsibilities at Vertex, Charlie serves on the board of directors for The TJX Companies, Inc. and is a member of its Audit and Finance Committee. In 2023 and 2024, he was named to the global Empower Role Model Top 50 Advocate List in recognition of his leadership in driving inclusion and equity within the workplace and the community.

Nia has extensive experience in global regulatory affairs in the pharmaceutical industry. She joined Vertex in 2017, and she provides global regulatory leadership and manages all regulatory interactions and quality assurance involving the research and development, manufacturing and commercialization of our medicines. In addition to creating and executing the company’s global regulatory strategy, Nia also manages a worldwide team of regulatory professionals. 

She graduated with a B.S. in biology from Temple University and a Ph.D. in cell and molecular biology from the University of Vermont. Before joining Vertex, she held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer and Wyeth.  

In addition to her responsibilities at Vertex, Nia serves on the board of directors for Verve Therapeutics. In 2024, she was named to the Endpoints News Women Leading Biopharma R&D list and the PharmaVoice 100. She was previously named to Fierce Pharma's Fiercest Women in Life Sciences list.

Amit joined Vertex in 2007 and has dedicated more than 15 years of his career to various leadership positions across Vertex, including establishing our first international commercial operations in 2010. Amit oversees Vertex’s government affairs and public policy, patient and community engagement, medical affairs and external affairs functions. He leads Vertex’s efforts to build and strengthen relationships with patient, medical and community partners and external stakeholders globally.

He earned a B.S. from Carnegie Mellon University and a J.D. from Emory University. Prior to Vertex he held roles with the Biotechnology Innovation Organization (BIO), the U.S. Food and Drug Administration and the U.S. House of Representatives.

Carmen has deep experience leading global clinical development programs across all phases of development and across multiple diseases and therapeutic modalities. She joined Vertex in 2019 and is responsible for developing and driving the execution of our clinical development programs, including clinical development, medical affairs, drug safety, global clinical operations and biometrics. 

She graduated with her medical degree from McGill University, where she also completed a residency in internal medicine and served as Chief Resident. She completed a combined fellowship in pulmonary and critical care medicine at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. 

Carmen serves as a member of the Clinical Advisory Committee at Akili Interactive. Previously she was the industry representative to the U.S. Food and Drug Administration’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical Development Committee. 

Stuart joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Operating Officer, he oversees Vertex’s global commercial team, which includes activities that support the approved use of Vertex’s marketed medicines around the world. He also leads the program and portfolio management, human resources and corporate communications functions.

He graduated with a degree in pharmacology and physiology from the University of Leeds in the United Kingdom, and prior to Vertex, he held multiple leadership roles at Amgen and GlaxoSmithKline (GSK) plc.  

Stuart serves on the board of directors for Rhythm Pharmaceuticals and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.